Strategy for growth

Every day, we strive to build a broader and stronger Orexo. By doing so, we can improve many more lives, foster a more dynamic work environment, and generate value for our shareholders. Our efforts to strengthen and expand Orexo are built on three pillars and are driven by our ambition to contribute to a more sustainable world for all.

  • Maintain Zubsolv® revenues in local currency.
  • Approval and launch of Izipry®.
  • Milestone payments and royalties from current and future partnered products.

  • Expand reimbursement of Zubsolv in the public segment and maintain access in the commercial segment.
  • Secure reimbursement for Izipry at launch.
  • Establish collaborations under MATCore® to provide innovative solutions that improve access to OUD treatment.

  • Advance internal rescue medications and out-license products based on the AmorphOX® technology such as OX640.
  • Expand into large molecules through partnership and improve scientific proof of concept.
  • Partner with CDMO1 and other partners to expand reach of technology. 

1 Contract Development and Manufacturing Organization

 

 

 

Sustainability strategy

Orexo’s business strategy and its day-to-day operationalization are shaped by the company’s Ethical Code. The strategy supports Agenda 2030 and the Sustainable Development Goals (SDGs). It is also aligned with global standards and initiatives, including the International Labor Organization Conventions, and the UN Guiding Principles on Business and Human Rights. The sustainability strategy consists of four focus areas:

Responsible business

Focus area 1

Access to healthcare

Focus area 2

Sustainable employees

Focus area 3

Environment & climate action

Focus area 4